[go: up one dir, main page]

NO20034452L - Sykdoms-assosiert protein - Google Patents

Sykdoms-assosiert protein

Info

Publication number
NO20034452L
NO20034452L NO20034452A NO20034452A NO20034452L NO 20034452 L NO20034452 L NO 20034452L NO 20034452 A NO20034452 A NO 20034452A NO 20034452 A NO20034452 A NO 20034452A NO 20034452 L NO20034452 L NO 20034452L
Authority
NO
Norway
Prior art keywords
disease
associated protein
protein
Prior art date
Application number
NO20034452A
Other languages
English (en)
Other versions
NO20034452D0 (no
NO331277B1 (no
Inventor
Thierry Leveillard
Saddek Mohand-Said
Jose Alain Sahel
David Hicks
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20034452D0 publication Critical patent/NO20034452D0/no
Publication of NO20034452L publication Critical patent/NO20034452L/no
Publication of NO331277B1 publication Critical patent/NO331277B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20034452A 2001-04-06 2003-10-03 Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit NO331277B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104712A FR2823221B1 (fr) 2001-04-06 2001-04-06 Sequences associees a la degenerescence retinienne et applications
PCT/EP2002/003810 WO2002081513A2 (en) 2001-04-06 2002-04-05 Disease-associated protein

Publications (3)

Publication Number Publication Date
NO20034452D0 NO20034452D0 (no) 2003-10-03
NO20034452L true NO20034452L (no) 2003-12-04
NO331277B1 NO331277B1 (no) 2011-11-14

Family

ID=8862037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034452A NO331277B1 (no) 2001-04-06 2003-10-03 Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit

Country Status (22)

Country Link
US (6) US7795387B2 (no)
EP (1) EP1379657B1 (no)
JP (2) JP4370428B2 (no)
KR (1) KR100913258B1 (no)
CN (1) CN1529753B (no)
AU (1) AU2002312794B8 (no)
BR (1) BRPI0208870B8 (no)
CA (1) CA2443345C (no)
CZ (1) CZ305800B6 (no)
EC (1) ECSP024345A (no)
ES (1) ES2597835T3 (no)
FR (1) FR2823221B1 (no)
HU (1) HU226307B1 (no)
IL (3) IL158013A0 (no)
MX (1) MXPA03009114A (no)
NO (1) NO331277B1 (no)
NZ (1) NZ528376A (no)
PL (1) PL213658B1 (no)
RU (1) RU2384586C2 (no)
SK (1) SK288465B6 (no)
WO (1) WO2002081513A2 (no)
ZA (1) ZA200307403B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823221B1 (fr) * 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US7261544B2 (en) 2003-05-21 2007-08-28 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
FR2870241B1 (fr) * 2004-05-13 2015-02-27 Novartis Ag Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
EP2027889A1 (en) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) New neuronal viability factor and use thereof
EP2281047B1 (en) 2008-04-15 2020-04-08 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
US8779093B2 (en) * 2008-09-10 2014-07-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuronal viability factor and use thereof
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
ES2774779T3 (es) 2011-10-27 2020-07-22 Wellstat Ophthalmics Corp Vectores que codifican el factor de viabilidad de conos derivado de bastones
US20150038557A1 (en) 2012-02-24 2015-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treatment of retinal degenerative diseases
DK2909232T3 (da) 2012-10-17 2020-06-08 Inst Nat Sante Rech Med Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af aldersrelateret makuladegeneration (amd)
CN112029791A (zh) 2013-07-31 2020-12-04 诺华股份有限公司 选择真核宿主细胞的选择载体和方法
WO2016185242A1 (en) 2015-05-21 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Synergistic combination of neuronal viability factors and uses thereof
US10857240B2 (en) 2016-01-05 2020-12-08 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of ocular disorders and blinding diseases
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
EP3526238A4 (en) 2016-10-11 2020-04-29 Wellstat Ophthalmics Corporation FUSION PROTEIN BETWEEN A SHORT-ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE
US20230146121A1 (en) * 2019-12-09 2023-05-11 Chigenovo Co., Ltd. Use of cyp4v2 and rdcvf in the manufacture of medicament
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
EP4366757A1 (en) * 2021-07-07 2024-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
CN113774019B (zh) * 2021-08-11 2024-02-13 东南大学 一种脐带血间充质干细胞无血清培养基、培养方法及其应用
US20240342313A1 (en) 2023-03-30 2024-10-17 Pharma Cinq, Llc Vector encoding rod-derived cone viability factor and human igk signal sequence

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
GB9701710D0 (en) * 1997-01-28 1997-03-19 Karobio Ab Mammalian protein
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
FR2784030B1 (fr) * 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
FR2784898A1 (fr) * 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
FR2823221B1 (fr) 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US8779093B2 (en) 2008-09-10 2014-07-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuronal viability factor and use thereof

Also Published As

Publication number Publication date
IL158013A0 (en) 2004-03-28
MXPA03009114A (es) 2004-11-22
US20120108657A1 (en) 2012-05-03
US8957043B2 (en) 2015-02-17
US20040204350A1 (en) 2004-10-14
US20090062188A1 (en) 2009-03-05
US8394756B2 (en) 2013-03-12
HU226307B1 (en) 2008-08-28
US7795387B2 (en) 2010-09-14
JP2009232843A (ja) 2009-10-15
NZ528376A (en) 2005-09-30
IL158013A (en) 2010-12-30
FR2823221B1 (fr) 2004-04-02
WO2002081513A2 (en) 2002-10-17
JP2005502319A (ja) 2005-01-27
ZA200307403B (en) 2004-04-21
NO20034452D0 (no) 2003-10-03
CA2443345A1 (en) 2002-10-17
EP1379657B1 (en) 2016-08-17
KR20030094317A (ko) 2003-12-11
BR0208870A (pt) 2004-04-27
SK288465B6 (sk) 2017-06-02
KR100913258B1 (ko) 2009-08-21
US8114849B2 (en) 2012-02-14
ECSP024345A (es) 2004-06-28
US8518695B2 (en) 2013-08-27
CA2443345C (en) 2012-12-04
US20120108523A1 (en) 2012-05-03
US8071745B2 (en) 2011-12-06
RU2384586C2 (ru) 2010-03-20
EP1379657A2 (en) 2004-01-14
JP4370428B2 (ja) 2009-11-25
CN1529753B (zh) 2013-06-12
CZ20032706A3 (cs) 2003-12-17
WO2002081513A3 (en) 2003-05-01
IL199316A (en) 2011-01-31
SK12232003A3 (sk) 2004-03-02
PL364681A1 (en) 2004-12-13
NO331277B1 (no) 2011-11-14
US20080004231A1 (en) 2008-01-03
HUP0303730A2 (en) 2006-02-28
JP4571695B2 (ja) 2010-10-27
US20130287738A1 (en) 2013-10-31
RU2003130638A (ru) 2005-04-20
ES2597835T3 (es) 2017-01-23
CN1529753A (zh) 2004-09-15
BRPI0208870B8 (pt) 2021-05-25
FR2823221A1 (fr) 2002-10-11
CZ305800B6 (cs) 2016-03-23
AU2002312794B2 (en) 2005-12-01
BRPI0208870B1 (pt) 2016-01-12
AU2002312794B8 (en) 2006-01-12
PL213658B1 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
DE50204184D1 (de) Espressobrüheinrichtung
NO20034774D0 (no) Melanokortinreseptorligander
DK1421841T3 (da) Mejetærsker
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
DE50208022D1 (de) Wischblatt
DE50206021D1 (de) Schlauchklemme
DE50204386D1 (de) Kreuztransducer
DE50103741D1 (de) Welle-Nabe-Verbindung
NO20034452L (no) Sykdoms-assosiert protein
ATE335486T1 (de) Hydrazono-malonitrile
DE60208317D1 (de) Ozonisator
DE50204551D1 (de) Kugelgelenk
IS2523B (is) Turn vindorkuvers
DE50204794D1 (de) Kugelgelenk
DE50203984D1 (de) Kugelgelenk
DE50203412D1 (de) Schwenkkolbenverdränger
DE50208029D1 (de) Kugelgelenk
ATE355059T1 (de) Isoxazolopyridinone
DE50203093D1 (de) Losradlager
NO20032963D0 (no) Peptidforbindelser
ATE319694T1 (de) Phenylalkyne
ATA18372001A (de) Gelenksbolzenbaueinheit
DE60232564D1 (de) Fixiergerät
DE50202088D1 (de) Garmodulsystem
DE50207815D1 (de) Kugelgelenk

Legal Events

Date Code Title Description
MK1K Patent expired